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a patient on LTP with recurrent bleedings. Methods: A cost-consequences analysis 
was adopted to assess the economic impact from the NHS and Society perspectives. 
The cost analysis was based on one patient case (type 1 VWD, recurrent gum bleed-
ings), treated with FVIII/VWF and then with VWF concentrate almost devoid of FVIII. 
The costs included direct costs (drug acquisition, hospital admissions, outpatient 
visits, red blood cells units) and indirect costs (working days lost). Data were gathered 
from a questionnaire (Hemophilia Reference Center of Catania). The health care costs 
were calculated by DRG analysis that assessed DRG refund value for day hospital 
and standard hospitalization. The indirect costs were calculated on the basis of the 
annual income average. Results: The analysis showed a reduction of the number 
of bleedings when treating with VWF concentrate almost devoid of FVIII (30 vs 0), 
minimizing the cost per bleeding episodes (€ 87,957 vs € 0), hospitalizations (€ 3,252 vs 
0), monitoring visits (€ 331 vs € 165) and the number of working days lost (26 vs 2). The 
annual health care costs and indirect costs avoided were € 49,684 and € 3,734 respec-
tively. ConClusions: The replacement therapy with VWF concentrate almost devoid 
of FVIII decreased the consumption of hospital resources and reduced the number 
of working days lost per bleedings together with the discomfort related to bleedings.
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objeCtives: TPO-RAs, represent an evidence-based treatment option in the pub-
lic setting for adult patients with chronic ITP in Mexico. TPO-RAs have not been 
directly compared in head-to-head randomized controlled trials (RCTs); however 
an indirect comparison was undertaken using Bayesian metaregression: the overall 
platelet response was significantly higher in patients receiving Romiplostim than 
in those receiving Eltrombopag, estimating an Odds ratio (OR) of eltrombopag vs 
romiplostim as 0.15 (95% CI: 0.02, 0.84). The objective of this study is to compare 
the cost per response of TPO-RAs in chronic adult ITP in Mexico. Methods: A cost 
per response analysis was developed. Dose was derived from RCTs and Summary 
of Product Characteristics. Median dose for romiplostim was 2.5 mcg/kg/week and 
average dose for eltrombopag was 55 mg/day (21.5% of patients received 25mg; 
41% 75mg; and remaining 37.5% 50mg). Costs for romiplostim were based on vials 
used, considering a representative Mexican patient (65kg); for eltrombopag, it was 
based on milligrams needed. Cost assessment included cost of medication, cost of 
administration and in case of eltrombopag, cost of liver monitoring, expressed in 
Mexican pesos. Crude Overall Response Rate (ORR) for romiplostim was 83%. Placebo 
adjusted ORR for eltrombopag was 42% calculated by applying the OR estimated 
from the Bayesian indirect comparison performed by the NICE Evidence Review 
Group. Results: Romiplostim generates a cost per overall platelet response of 
$219,690.80, while eltrombopag yields $374,137.72. ConClusions: Within the TPO-
RAs, romiplostim generates a lower cost per response than eltrombopag, in adult 
patients with chronic ITP in Mexico.
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objeCtives: Belimumab is a novel biological treatment specifically developed for 
the treatment of active, autoantibody positive SLE patients. The purpose of this study 
is to estimate the cost-effectiveness of belimumab for SLE patients from the Spanish 
societal perspective. Methods: A UK cost-effectiveness microsimulation model 
was adapted to the Spanish setting. The analysis compared standard of care (SoC) 
vs. belimumab plus SoC with 2 years maximum treatment duration and a life-time 
horizon. Disease activity reduction seen with belimumab in the BLISS-52 and BLISS-
76 trials, was extrapolated using data from the US Johns Hopkins Lupus Cohort to 
predict impact on long-term organ damage and mortality.. Utility values and unit 
direct costs (treatment, administration, patient´s follow-up and organ damage costs) 
were obtained from UK and Spain published data, respectively. Indirect costs were 
calculated using the Human Capital Approach method. A discount rate of 3% was 
applied to costs and outcomes. Results were expressed as € 2014. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to determine the robust-
ness of the results. An additional analysis was conducted to compare societal and 
Spanish National Health System (NHS) perspectives. Results: The cost per life year 
gained (ICER) and cost per QALY (ICUR) for Belimumab were € 16,647 and € 23,158 
respectively. In 68% of scenarios plotted in the PSA, belimumab was a cost-effective 
alternative considering a € 30,000/QALY threshold. From NHS perspective (indirect 
costs excluded), ICER and ICUR were € 25.619 and € 35.640. ConClusions: Base-case 
results show that belimumab is cost-effective from the Spanish societal perspective. 
From the NHS perspective, the model provides results that fall within an acceptable 
threshold considering the prevalence and the severity of the disease. These results 
highlight the importance of adopting a societal perspective, especially in pathologies 
such as SLE which affect young people of working age.
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objeCtives: Evaluate the efficiency of rituximab in maintenance treatment of 
patients with follicular lymphoma (FL) who respond to first line induction with 
rituximab versus observation in Portugal. Methods: Cost-effectiveness (Life 
(vs. all OCs) had lower activity impairment and fewer provider visits, lower indirect 
costs (normal weight: € 7,974; overweight: € 7,825; OC I: € 8,465; OC II: € 9,394; OC III: 
€ 10,437), and lower total direct costs (normal weight: € 516; overweight: € 553; OC I: 
€ 583; OC II: € 605; OC III: € 717), all p< 0.05. ConClusions: Increased BMI is associ-
ated with higher direct and indirect costs and worse health utilities. The findings 
highlight the impact of obesity on health outcomes.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common genetic kidney disease. Currently there is little published information on 
medical resource utilisation (MRU) in European ADPKD patients. This study aimed 
to estimate the health care resource use of ADPKD patients across six European 
countries. Methods: A retrospective review of medical charts was conducted via 
an online physician survey in France, Germany, Italy, Spain, Sweden and the United 
Kingdom (UK). A total of 353 physicians were recruited to review MRU over the previ-
ous 24 month period from the records of 1,055 patients, with each clinician selecting 
the last three patients representing three different chronic kidney disease stages. 
Data collected included patient characteristics and MRU such as tests, visits, hospi-
talisations and medications. Results: The proportion of patients who had a kidney 
ultrasound during the 24 months study period varied from 20.0% in Sweden to 68.0% 
in Germany. In all countries, except Germany (66.0%), at least 90% of patients had 
one or more contact with a specialist. Annualised specialist visits varied from 2.7 
(SD 7.9) in Germany to 6.0 (SD 10.7) in Sweden. Germany had the largest proportion 
of patients with hospitalisations related to ADPKD (25.7%) whereas Sweden had 
the lowest (13.3%). Hospital length of stay was longest in Spain (mean, 8.5 days (SD 
6.2)) and shortest in the UK (mean, 4.7 days (SD 3.8)). In terms of medication use, 
32.7% of German patients were prescribed loop diuretics whereas this proportion 
was 9.0% in the UK. The UK had the highest rate of opioid use for renal pain overall 
(8.7%) and among patients on dialysis (27.3%). ConClusions: This is the first study 
to provide comparative evidence on MRU in European patients with ADPKD. Results 
highlight some country-specific differences in treatment patterns, including rates 
of hospitalisation, frequency of specialist visits and medication use.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common type of polycystic kidney disease (PKD) and the fourth leading cause of end-
stage renal disease. Currently, there is no published information on medical resource 
utilisation (MRU) in patients with ADPKD in Europe. This study aimed to better 
understand MRU associated with ADPKD by disease stage in six European countries 
(Germany, France, the United Kingdom, Italy, Spain and Sweden). Methods: This 
study was a retrospective review of medical charts collected via an online physician 
survey. Participating physicians abstracted data for the last three eligible ADPKD 
patients treated in their practice, each within a different Chronic Kidney Disease 
(CKD) stage. Data collected over the past 2 years included socio-demographics, 
clinical characteristics and MRU, such as diagnostic tests, specialist visits, dialysis, 
emergency department visits, inpatient admissions and medications. Results: 
A total of 1,055 ADPKD patients were enrolled. The mean (SD) age of the sample 
was 50.4 (14.4) years, 53.6% were male, with 39.4% employed full time. Only 40% of 
patients had a known PKD genotype, of which 83% had PKD-1 and 17% had PKD-
2. Almost all patients (99.1%) experienced at least 1 ADPKD-related complication, 
most commonly hypertension (75.4%). On average (SD), patients had 4.4 (9.3) annual 
specialist visits. Approximately 19.7% of patients experienced at least 1 hospitalisa-
tion over the 2 year study period with a mean (SD) length of stay of 7.0 (8.5) days. 
Patients in more advanced disease stages reported higher mean (SD) annual spe-
cialist visits and more disease-related hospitalisations, 1.5 (1.1) and 9.2% in CKD 
Stage 1 compared to 10.0 (17.2) and 32.4% in Dialysis, respectively. ConClusions: 
This is the first study to provide evidence on MRU among patients with ADPKD in 
Europe. Results demonstrate that ADPKD patients require substantial MRU, which 
accumulate with disease progression.
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objeCtives: Von Willebrand Disease (VWD) is the most common inherited bleeding 
disorder, caused by a deficiency or abnormality of the Von Willebrand factor (VWF). 
Long-term prophylaxis (LTP) with Factor VIII-containing VWF product (FVIII/VWF) is 
used for patients with severe VWD. However, FVIII/VWF is not enough effective in 
some cases. Furthermore repeated infusions of FVIII/VWF may increase the risk of 
thromboembolic events. The objective of the analysis was to assess the economic 
impact of VWF concentrate almost devoid of FVIII as an alternative to FVIII/VWF for 
